文献速递核素与放射性配体治疗

从均匀到异质性剂量模型:[177Lu]Lu-DOTATATE与[161Tb]Tb-DOTATATE的细胞与肿瘤吸收剂量-效应关系

From uniform to heterogeneous dose models: connecting cellular and tumor absorbed dose-response for [177Lu]Lu-DOTATATE and [161Tb]Tb-DOTATATE.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-02-09

本研究在CA20948异种移植小鼠中比较了[177Lu]Lu-DOTATATE与[161Tb]Tb-DOTATATE的肿瘤吸收剂量-效应关系。结果显示肿瘤倍增时间与肿瘤吸收剂量正相关(p < 0.0001,R2 = 0.58),两种药物间无显著差异(p = 0.24)。考虑肿瘤内吸收剂量异质性后模型性能提升,且[161Tb]Tb-DOTATATE未显示优于[177Lu]Lu-DOTATATE的疗效。

要点

  • 肿瘤倍增时间与肿瘤吸收剂量正相关,受肿瘤内异质性分布影响。
  • [161Tb]Tb-DOTATATE与[177Lu]Lu-DOTATATE的剂量-效应无显著差异。
  • 考虑亚肿瘤吸收剂量异质性可改善肿瘤生长模型性能。

核心结论

  • 肿瘤倍增时间与肿瘤吸收剂量呈正相关,且很大程度上受肿瘤内异质性吸收剂量分布影响。
  • 研究证实[161Tb]Tb-DOTATATE相比[177Lu]Lu-DOTATATE并未提高治疗疗效。

研究设计与样本

  • 使用CA20948异种移植荷瘤小鼠,注射[177Lu]Lu-DOTATATE(1 nmol,21.6–115.4 MBq)和[161Tb]Tb-DOTATATE(1 nmol,17.3–91.7 MBq)。
  • 测量肿瘤倍增时间并与micro-SPECT成像确定的个体肿瘤吸收剂量进行相关性分析。
  • 基于细胞吸收剂量-效应关系建模肿瘤生长,并考虑数字放射自显影或micro-SPECT确定的亚肿瘤吸收剂量分布。

主要发现

  • [161Tb]Tb-DOTATATE在肿瘤中的S值较[177Lu]Lu-DOTATATE高30%(经亚细胞异质性校正后)。
  • [177Lu]Lu-DOTATATE和[161Tb]Tb-DOTATATE分别达到临床相关肿瘤吸收剂量范围9–85 Gy和5–87 Gy。
  • 肿瘤倍增时间与肿瘤吸收剂量呈正相关(p < 0.0001,R2 = 0.58)。
  • [177Lu]Lu-DOTATATE与[161Tb]Tb-DOTATATE的剂量-效应无显著差异(p = 0.24)。
  • 考虑吸收剂量异质性后肿瘤生长模型性能从R2 = -64提升至R2 = 0.16。

临床怎么用

  • 临床个性化剂量方案制定时需考虑肿瘤内吸收剂量的异质性分布。
  • [161Tb]Tb-DOTATATE不宜被视为较[177Lu]Lu-DOTATATE更有效的治疗选择。

局限性

  • 研究为临床前小鼠模型,结论外推至临床需谨慎。
  • 模型性能在考虑异质性后仍有限(R2 = 0.16)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Knowledge of tumor absorbed dose (AD)–response relationships is a critical first step toward personalizing dose regimens. This study investigated these relationships at a preclinical scale and modeled the observed tumor growth by considering both cellular AD-response relationships and tumor AD distributions. Using this framework, we compared the tumor AD-response of [177Lu]Lu-DOTATATE and [161Tb]Tb-DOTATATE. METHODS: CA20948 xenograft-bearing mice were injected with a range of activities of [177Lu]Lu-DOTATATE (1 nmol, 21.6–115.4 MBq) and [161Tb]Tb-DOTATATE (1 nmol, 17.3–91.7 MBq). The tumor doubling time was measured and correlated with individual tumor AD, determined with micro-SPECT imaging. The tumor-growth was also modeled based on cellular AD-response relationships, while considering subtumor AD distributions that were determined either with digital autoradiography or micro-SPECT. RESULTS: [161Tb]Tb-DOTATATE showed a 30% higher S-value for tumors compared to [177Lu]Lu-DOTATATE, after a correction for subcellular heterogeneity. Both treatments reached a clinically relevant tumor AD-range of 9–85 Gy and 5–87 Gy, respectively. A positive correlation was observed between the tumor doubling time and the tumor AD (p < 0.0001, R2 = 0.58), with no significant difference in AD-response between [177Lu]Lu-DOTATATE and [161Tb]Tb-DOTATATE (p = 0.24). The performance of the tumor-growth-model improved substantially after considering AD heterogeneity (from R2 = -64 up to R2 = 0.16). CONCLUSION: The tumor doubling time showed a positive correlation with the tumor AD which was largely affected by the heterogeneous AD distribution within the tumor. Findings confirm that [161Tb]Tb-DOTATATE does not increase the therapeutic efficacy compared to [177Lu]Lu-DOTATATE.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Spoormans K, Struelens L, Koole M, et al. From uniform to heterogeneous dose models: connecting cellular and tumor absorbed dose-response for [177Lu]Lu-DOTATATE and [161Tb]Tb-DOTATATE. Eur J Nucl Med Mol Imaging. 2026. PMID: 41656422. doi:10.1007/s00259-026-07770-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。